Interpretation of coagulation test results under direct oral anticoagulants

International Journal of Laboratory Hematology

Volumn 36, Issue 3, 2014, Pages 261-268

  Mani, H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anticoagulants; Apixaban; Dabigatran; Laboratory; Rivaroxaban; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; ARGATROBAN; DABIGATRAN; HIRUDIN; PROTEIN S; RIVAROXABAN; WARFARIN;

BLOOD CLOTTING TEST; CHROMOGENIC FACTOR XA ASSAY; DRUG MONITORING; HEMATOLOGY TEST KIT; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; THROMBIN TIME; BLOOD; BLOOD CLOTTING; BLOOD COAGULATION DISORDERS; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; HUMANS; TREATMENT OUTCOME;

EID: 84898678739     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12235     Document Type: Review

References (26)

1. Poller L, Ibrahim S, Keown M, Pattison A, Jespersen J, European Action On Anticoagulation. The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers-two independent studies. J Thromb Haemost 2011;9:140-8.
2. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(Suppl. 2):e44S-88S.
3. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. American College of Chest Physicians. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2008;133(Suppl. 6):S160-98.
4. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
5. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011;106:156-64.
6. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogné JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res 2012;130:956-66.
7. Harenberg J, Marx M, Krämer R, Giese C, Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 2011;22:637-41.
8. EMA-Rivaroxaban 2012-Summary of Product Characteristics
9. Douxfils J, Chatelain C, Chatelain B, Dogné JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost 2013;110:283-94.
10. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Hillarp A. Expert Group on Coagulation of the External Quality Assurance in Laboratory Medicine in Sweden. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 2011;105:371-8.
11. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogné JM. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 2012;107:985-97.
12. Herth N, Mani H, Wenger F, Meurer A, Marzi I, Lindhoff-Last E. Dabigatran influences ex-vivo global coagulation assays in dependence of time of drug intake. Hämostaseologie 2011;A89:P17.5.
13. EMA-Dabigatran 2013-SPC
14. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012;23:138-43.
15. Klaeffling C, Piechottka G, Daemgen-von Brevern G, Mosch G, Mani H, Luxembourg B, Lindhoff-Last E. Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Ther Drug Monit 2006;28:375-81.
16. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL. Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107:379-87.
17. Harenberg J, Krämer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 2011;32:267-71.
18. Asmis LM, Alberio L, Angelillo-Scherrer A, Korte W, Mendez A, Reber G, Seifert B, Stricker H, Tsakiris DA, Wuillemin WA. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 2012;129:492-8.
19. Mani H, Rohde G, Stratmann G, Lindhoff-Last E. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012;108:191-8.
20. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S, Siguret V, Lecompte T. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost 2014;111:240-8.
21. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 2013;109:127-36.
22. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21.
23. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, Yu Z, Shenker A, Barrett YC, Mosqueda-Garcia R, Lacreta F. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol 2013;76:776-86.
24. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95.
25. Mani H, Kasper A, Lindhoff-Last E. Measuring the anticoagulant effects of target specific oral anticoagulants-reasons, methods and current limitations. J Thromb Thrombolysis 2013;36:187-94.
26. Tripodi A. The laboratory and the direct oral anticoagulants. Blood 2013;121:4032-5.